![]() |
Name |
Lobophorin I
|
Molecular Formula | C61H88N2O21 | |
IUPAC Name* |
methyl N-[(2S,3S,4R,6R)-6-[[(3S,6R,13R,16R,17R,18R,20R,21S,22R)-4-formyl-23-hydroxy-17-[(2S,4R,5S,6S)-5-hydroxy-4-[(2R,4R,5R,6S)-4-hydroxy-5-[(2R,4R,5R,6S)-4-hydroxy-5-methoxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-3,8,12,18,20,22-hexamethyl-25,27-dioxo-26-oxapentacyclo[22.2.1.01,6.013,22.016,21]heptacosa-4,7,11,14,23-pentaen-9-yl]oxy]-2,4-dimethyl-4-nitrooxan-3-yl]carbamate
|
|
SMILES |
C[C@@H]1C[C@H]([C@H]([C@H]2[C@H]1[C@@]3([C@H](C=C2)C(=CCC(C(=C[C@@H]4C=C([C@H](CC45C(=O)C(=C3O)C(=O)O5)C)C=O)C)O[C@H]6C[C@@]([C@@H]([C@@H](O6)C)NC(=O)OC)(C)[N+](=O)[O-])C)C)O[C@@H]7C[C@H]([C@H]([C@@H](O7)C)O)O[C@@H]8C[C@H]([C@H]([C@@H](O8)C)O[C@@H]9C[C@H]([C@H]([C@@H](O9)C)OC)O)O)C
|
|
InChI |
InChI=1S/C61H88N2O21/c1-27-14-17-42(80-47-25-59(10,63(72)73)54(35(9)79-47)62-58(71)75-13)28(2)19-37-20-36(26-64)31(5)24-61(37)56(69)48(57(70)84-61)55(68)60(11)39(27)16-15-38-49(60)29(3)18-30(4)51(38)82-46-23-43(50(67)32(6)76-46)81-44-22-41(66)53(34(8)78-44)83-45-21-40(65)52(74-12)33(7)77-45/h14-16,19-20,26,29-35,37-47,49-54,65-68H,17-18,21-25H2,1-13H3,(H,62,71)/t29-,30-,31+,32+,33+,34+,35+,37-,38-,39-,40-,41-,42?,43-,44-,45-,46-,47+,49+,50+,51-,52+,53+,54-,59-,60+,61?/m1/s1
|
|
InChIKey |
FKPHBCYNXIGWLW-OZRRPFOLSA-N
|
|
Synonyms |
Lobophorin I
|
|
CAS | NA | |
PubChem CID | 139584450 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 1185.3 | ALogp: | 5.5 |
HBD: | 5 | HBA: | 21 |
Rotatable Bonds: | 12 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 309.0 | Aromatic Rings: | 9 |
Heavy Atoms: | 84 | QED Weighted: | 0.038 |
Caco-2 Permeability: | -5.469 | MDCK Permeability: | 0.00049991 |
Pgp-inhibitor: | 0.998 | Pgp-substrate: | 1 |
Human Intestinal Absorption (HIA): | 0.13 | 20% Bioavailability (F20%): | 0.008 |
30% Bioavailability (F30%): | 0.192 |
Blood-Brain-Barrier Penetration (BBB): | 0.001 | Plasma Protein Binding (PPB): | 77.90% |
Volume Distribution (VD): | 1.471 | Fu: | 10.90% |
CYP1A2-inhibitor: | 0 | CYP1A2-substrate: | 0.649 |
CYP2C19-inhibitor: | 0.02 | CYP2C19-substrate: | 0.508 |
CYP2C9-inhibitor: | 0.021 | CYP2C9-substrate: | 0.001 |
CYP2D6-inhibitor: | 0.001 | CYP2D6-substrate: | 0.033 |
CYP3A4-inhibitor: | 0.864 | CYP3A4-substrate: | 0.933 |
Clearance (CL): | 7.069 | Half-life (T1/2): | 0.111 |
hERG Blockers: | 0.261 | Human Hepatotoxicity (H-HT): | 0.991 |
Drug-inuced Liver Injury (DILI): | 0.988 | AMES Toxicity: | 0.963 |
Rat Oral Acute Toxicity: | 0.933 | Maximum Recommended Daily Dose: | 0.997 |
Skin Sensitization: | 0.149 | Carcinogencity: | 0.016 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.005 |
Respiratory Toxicity: | 0.978 |